Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia

por Jamieson, Gene C., Fox, Judith A., Poi, Ming, Strickland, Stephen A.
Publicado 2016

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

por Aslan, Burcu, Hubner, Stefan Edward, Fox, Judith A., Taverna, Pietro, Wierda, William G., Kornblau, Steven M., Gandhi, Varsha
Publicado 2021

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

por Scatena, Caroline D., Kumer, Jeffrey L., Arbitrario, Jennifer P., Howlett, Anthony R., Hawtin, Rachael E., Fox, Judith A., Silverman, Jeffrey A.
Publicado 2010

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

por Hawtin, Rachael E., Stockett, David E., Byl, Jo Ann W., McDowell, Robert S., Tan, Nguyen, Arkin, Michelle R., Conroy, Andrew, Yang, Wenjin, Osheroff, Neil, Fox, Judith A.
Publicado 2010

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models

por Gravina, Giovanni Luca, Mancini, Andrea, Mattei, Claudia, Vitale, Flora, Marampon, Francesco, Colapietro, Alessandro, Rossi, Giulia, Ventura, Luca, Vetuschi, Antonella, Di Cesare, Ernesto, Fox, Judith A., Festuccia, Claudio
Publicado 2017

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

por Cheng, Pingyan, Chen, Xianghong, Dalton, Robert, Calescibetta, Alexandra, So, Tina, Gilvary, Danielle, Ward, Grace, Smith, Victoria, Eckard, Sterling, Fox, Judith A., Guenot, Jeanmarie, Markowitz, Joseph, Cleveland, John L., Wright, Kenneth L., List, Alan F., Wei, Sheng, Eksioglu, Erika A.
Publicado 2022

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

por Stuart, Robert K, Cripe, Larry D, Maris, Michael B, Cooper, Maureen A, Stone, Richard M, Dakhil, Shaker R, Turturro, Francesco, Stock, Wendy, Mason, James, Shami, Paul J, Strickland, Stephen A, Costa, Luciano J, Borthakur, Gautam, Michelson, Glenn C, Fox, Judith A, Leavitt, Richard D, Ravandi, Farhad
Publicado 2015

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

por Allan, John N., Pinilla-Ibarz, Javier, Gladstone, Douglas E., Patel, Krish, Sharman, Jeff P., Wierda, William G., Choi, Michael Y., O’Brien, Susan M., Shadman, Mazyar, Davids, Matthew S., Pagel, John M., Yimer, Habte A., Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L., Fox, Judith A., Furman, Richard R., Brown, Jennifer R.
Publicado 2021